Photoactivation of pheophorbide-a utilizing 670 nm LEDs elicits cancer suppressive effects in androgen-independent prostate cancer cellular models

J Pharm Pharmacol. 2023 Dec 8;75(12):1544-1559. doi: 10.1093/jpp/rgad083.

Abstract

Objectives: Prostate cancer (PCa) is the most commonly diagnosed cancer and the second leading cause of cancer death in men in the USA. Photodynamic therapy (PDT) is a state-of-the-art treatment that combines high selectivity with minor side effects. Pheophorbide-a (Pheo) is a natural pigment with a photosensitizer property. Our study delved into the impact of Pheo alone or Pheo-PDT combination on the androgen-independent metastatic prostate cancer (AIPC) cell lines DU-145 and C4-2. Furthermore, an in-depth examination has been conducted on the photocytotoxicity mechanism of Pheo-PDT in these specific cell lines.

Methods: In vitro studies were conducted using the AIPC cell lines. DU-145 and C4-2 cells were treated with Pheo at different concentrations for 60 min alone, or Pheo treatment followed by exposure to 670 nm illumination (60 mW/cm2 in 88 s pulses), producing 5 J/cm2 via portable light-emitting diode.

Key findings: Our results show that Pheo-PDT substantially inhibits cell viability, anchorage-independent growth, and migration capacities and induces autophagy and apoptosis via the over-production of reactive oxygen species that mediates endoplasmic reticulum stress in AIPC cell lines.

Conclusions: Our study highlights the potential benefits of Pheo-PDT in metastatic hormone-insensitive PCa cell lines. It paves the way for treating localized and locally advanced PCa as a possible candidate for castration-resistant prostate cancer.

Keywords: Prostate cancer; androgen-independent prostate cancer (AIPC); metastatic prostate cancer; pheophorbide-a; photocytotoxicity; photodynamic therapy (PDT).

MeSH terms

  • Androgens / metabolism
  • Androgens / pharmacology
  • Androgens / therapeutic use
  • Apoptosis
  • Cell Line, Tumor
  • Humans
  • Male
  • Photochemotherapy*
  • Photosensitizing Agents / pharmacology
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / pathology

Substances

  • Androgens
  • VA 061
  • Photosensitizing Agents